Abstract
Background
Pruritus is a debilitating symptom of cholestatic diseases such as primary biliary cholangitis and primary sclerosing cholangitis and often results in major reduction in quality of life for afflicted patients. Classic treatment options for the treatment of cholestatic pruritus include antihistamines, bile acid resins, serotonin reuptake inhibitors, and mu-opioid antagonists. Unfortunately, these drugs are not always successful in treating pruritus of cholestasis and may be associated with adverse effects. Recent advances in our understanding of itch pathophysiology have led to the use of butorphanol, a kappa-opioid agonist and mu-opioid antagonist, for the treatment of various forms of pruritus. Reports of butorphanol to treat cholestatic itch specifically are rare.
Aims
To better understand the role of butorphanol in the treatment of cholestatic pruritus, including characterization of its side effect profile.
Methods
We present a case series of eight adult patients with cholestatic disease who were treated with butorphanol in hopes of alleviating intractable pruritus. Patients were identified through a clinical data request form serviced by University of Miami Information Technology.
Results
Five out of eight patients (62.5%) reported successful reductions in itch severity after treatment with butorphanol, two patients reported no (or transient) change in itch severity, and one patient reported a paradoxical increase in itching. Side effects included somnolence, sedation, nausea, vomiting, and dizziness.
Conclusions
Butorphanol was safe and leads to clinically significant symptomatic improvement. Clinicians should be aware of butorphanol as an off-label treatment option for pruritus of cholestasis. Further studies are needed to better characterize the effect of butorphanol on cholestatic itch.
Similar content being viewed by others
References
Kremer AE, et al. Pathogenesis and management of pruritus in PBC and PSC. Dig Dis. 2015;33:164–175.
Gross CR, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology. 1999;29:356–364.
Beuers U, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399–407.
Yosipovitch G, Rosen JD, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142:1375–1390.
Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144:375–380.
Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54:527–531.
Bailey AG, et al. Epidural morphine combined with epidural or intravenous butorphanol for postoperative analgesia in pediatric patients. Anesth Analg. 1994;79:340–344.
Gunter J, et al. Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Pediatric Anesth. 2000;10:167–172.
Dunteman E, Karanikolas M, Filos KS. Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. J Pain Symptom Manag. 1996;12:255–260.
Carrion AF, Rosen JD, Levy C. Understanding and treating pruritus in primary biliary cholangitis. Clin Liver Dis. 2018;22:517–532.
Umeuchi H, et al. Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system. Eur J Pharmacol. 2003;477:29–35.
Togashi Y, et al. Antipruritic activity of the κ-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002;435:259–264.
Inan S, Cowan A. Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol. 2005;518:182–186.
Cowan A, Kehner GB, Inan S. Targeting itch with ligands selective for κ opioid receptors. Pharmacology of itch. New York: Springer; 2015:291–314.
Kumagai H, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transpl. 2010;25:1251–1257.
Kumada H, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47:972–982.
Kamimura K, et al. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PloS One. 2017;12:e0178991.
Jannuzzi RG. Nalbuphine for treatment of opioid-induced pruritus. Clin J Pain. 2016;32:87–93.
Hawi A, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol. 2015;16:47.
Fishbane, S., et al., Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney International Reports, 2020.
Fishbane S, et al. A phase 3 trial of Difelikefalin in hemodialysis patients with pruritus. New Engl J Med. 2020;382:222–232.
European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.
Lindor KD, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394–419.
Bolier R, Elferink RPO, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis. 2013;17:319–329.
Imam MH, et al. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012;27:1150–1158.
Tandon P, et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102:1528–1536.
Di CP, et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra-and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol. 1984;6:773–776.
Kremer AE, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56:1391–1400.
Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488–493.
Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26:943–948.
Bachs L, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992;102:2077–2080.
Webb G, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther. 2018;47:1213–1219.
Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2736–2741.
Mayo MJ, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–674.
Boozalis E, Khanna R, Kwatra SG. Selective serotonin reuptake inhibitors for the treatment of chronic pruritus. J Dermatol Treat. 2018;29:812–814.
Patel SP, et al. Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol. 2019;81:1371–1378.
Mosby D. Mosby’s Drug Consult. St Louis: Elsevier; 2005.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
CL received consulting fees from CymaBay, Genfit, Pliant, Shire, GSK, Mirum, TARGET PharmaSolutions and Cara Therapeutics, research grants from CymaBay, Intercept, Genfit, Shire, GSK, Cara Therapeutics, TARGET PharmaSolutions, Novartis, Durect, Enanta, Genkyotex, Gilead, Alnylam, and Mitsubishi. CL is an associate editor for Liver Transplantation, committee participant at ABIM and receives royalties from Up-to-Date. GY reports grants and personal fees from Sanofi Regeneron, personal fees from TREVI, grants and personal fees from Pfizer, personal fees from Galderma, grants from Sun Pharma, grants and personal fees from Kiniksa, grants and personal fees from Menlo, personal fees from Eli Lily, grants and personal fees from Novartis, personal fees from Bellus, grants and personal fees from Leo, outside the submitted work. RSG has no conflicts of interest to disclose.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Golpanian, R.S., Yosipovitch, G. & Levy, C. Use of Butorphanol as Treatment for Cholestatic Itch. Dig Dis Sci 66, 1693–1699 (2021). https://doi.org/10.1007/s10620-020-06392-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-020-06392-2